- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
iCAD to Highlight Mammo CAD, MRI Analysis, Colon CAD Products
Image analysis solutions provider iCAD Inc. will highlight several new features of their mammography CAD, MRI image analysis and colon CAD products.
Image analysis solutions provider iCAD Inc. will highlight several new features of their mammography CAD, MRI image analysis and colon CAD products.
In the company’s mammography line, the company will showcase its SecondLook Premier, a customizable mammography computer aided detection solution designed and developed using a 100 percent digital image database, the company said. The solution, which includes clinical decision support tools, is now available in Europe and company officials expect to receive FDA clearance for sale in the U.S. in 2012.
The company will also be demonstrating SecondLook Digital Multi-Vendor Solution, designed to work with the major digital mammography products as a practice expands.
iCAD will also be displaying its latest version of VersaVue enterprise software for MR image analysis, which has been optimized to improve speed and includes an upgraded user interface and automated templates for images and charts, said Peter Espo, vice president of global marketing.
iCAD will be featuring two partnerships in their MRI portfolio as works in progress - an MRI-guided prostate biopsy solution and a prostate MRI-TRUS fusion integration, Espo said.
Last month, the company entered in to a distribution agreement with Hitachi Medical Systems for iCAD’s SpectraLook with PrecisionPoint image analysis solution for breast MRI to be available with Hitachi’s Oasis and Echelon MRI systems.
Finally, iCAD will highlight its VeraLook CAD system for virtual colonoscopy, which was made available in 2010.
Can MRI-Based AI Bolster Biopsy Decision-Making in PI-RADS 3 Cases?
December 9th 2024In patients with PI-RADS 3 lesion assessments, the combination of AI and prostate-specific antigen density (PSAD) level achieved a 78 percent sensitivity and 93 percent negative predictive value for clinically significant prostate cancer (csPCa), according to research presented at the Radiological Society of North American (RSNA) conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
New Interventional Radiology Research Shows Merits of Genicular Artery Embolization for Knee OA
December 3rd 2024In a cohort of over 160 patients with knee osteoarthritis (OA), including grade 4 in nearly half of the cases, genicular artery embolization led to an 87 percent improvement in the quality of life index, according to research presented at the recent RSNA conference.
Siemens Healthineers Debuts New Photon-Counting CT Systems at RSNA
December 2nd 2024Debuting at the Radiological Society of North American (RSNA) conference, the new photon-counting computed tomography (PPCT) scanners Naeotom Alpha.Pro and Naeotom Alpha.Prime reportedly combine rapid scan times with high-resolution precision.
